Research programme: tubulin polymerisation inhibitors - Ipsen

Drug Profile

Research programme: tubulin polymerisation inhibitors - Ipsen

Alternative Names: IRC-083927; STX 140; STX 243; STX 2484; Tetrahydroisoquinoline-based compounds; THIQ-based compounds

Latest Information Update: 03 Dec 2010

Price : $50

At a glance

  • Originator Sterix
  • Developer Ipsen
  • Class Antineoplastics; Cyclopentanes; Phenanthrenes
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Microtubule protein inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 16 Nov 2010 Preclinical development is ongoing in the UK - compound optimisation update presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
  • 09 Sep 2010 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours presented at the 21st International Symposium on Medicinal Chemistry (ISMC-2010)
  • 21 Apr 2010 Preclinical pharmacodynamics data presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top